Global Atopic Dermatitis Market, By Drug Type (Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others), Type (Monoclonal Antibodies, Hormone, Erythropoietin, Calcitonin, Interferon, Others), Route of Administration (Injectable, Topical, Oral), Application (Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases, Others), End Users (Hospitals, Clinics, Research Centers Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Atopic Dermatitis Market
The atopic dermatitis market is expected to gain growth at a potential rate of 8.70% in the forecast period of 2021 to 2028 and is expected to reach a value of USD 8.68 billion by 2028. The strong product pipeline for atopic dermatitis is the factors for the market growth.
Atopic dermatitis is the type of eczema; patients who are suffering with this disease have super sensitive skin and a less threshold for irritation. Atopic dermatitis consists of hay fever, allergic asthma, atopic dermatitis, food allergies and anaphylaxis.
The rapid development of novel pipeline drugs is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rise in demand for new biologics and product approvals are also predictable to enhance the atopic dermatitis market growth. Furthermore, the favorable reimbursement policies in emerging countries and high prevalence of atopic dermatitis are also projected to drive the market growth rate. Also, the increase in awareness regarding the availability of treatments for the disease and various initiatives undertaken by governments to provide better and more affordable treatment are also expected to influence the atopic dermatitis market growth globally.
In addition, the rapid technological advancement and the rise in funding along with increase in government support for research and development are likely to create various new opportunities that will impact this atopic dermatitis market growth in the forecast period of 2021 to 2028.
However, the easy availability of expensive treatment and poor reimbursement policies in the developing regions across the globe are expected to act as major restraints towards the growth of the atopic dermatitis market, whereas the allergic reactions of off-label therapies and patent expiry of products can challenge the growth of the target market in the above mentioned forecast period.
This atopic dermatitis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the atopic dermatitis market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Atopic Dermatitis Market Scope and Market Size
The atopic dermatitis market is segmented on the basis of drug type, type, route of administration, application, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on drug type, the atopic dermatitis market is segmented into corticosteroids, PDE4 inhibitors, biologics, skin barrier emollients, CNI immunosuppressants and others.
- On the basis of type, the atopic dermatitis market is segmented into monoclonal antibodies, hormone, erythropoietin, calcitonin, interferon and others.
- Based on route of administration, the atopic dermatitis market is segmented into injectable, topical and oral.
- On the basis of application, the atopic dermatitis market is segmented into cancer, blood disorders, chronic diseases, infectious diseases, and others
- The atopic dermatitis market is also segmented on the basis of end users into hospitals, clinics, research centers and others.
- On the basis of distribution channel, the atopic dermatitis market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Atopic Dermatitis Market Country Level Analysis
The atopic dermatitis market is analyzed and market size information is provided by country by drug type, type, route of administration, application, end users and distribution channel as referenced above.
The countries covered in the atopic dermatitis market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the atopic dermatitis market due to well-developed technology, increase in patient with low quantity of protein filaggrin and rise in prevalence atopic disorder. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The atopic dermatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Atopic Dermatitis Market Share Analysis
The atopic dermatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to atopic dermatitis market.
The major players covered in the atopic dermatitis market report are Galderma, Pfizer Inc, Regeneron Pharmaceuticals, Inc, LEO Pharma A/S, Sanofi, Novartis AG, Bristol-Myers Squibb Company, Bayer AG, Bausch Health, Allergan, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, AbbVie Inc., Encore Dermatology, Inc., Astellas Pharma Inc., Mylan N.V., AstraZeneca, 3M, and Teva Pharmaceutical Industries Ltd., among other domestic and global players. Atopic dermatitis market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.